David Gandara, MD from the University of California, Davis, CA discusses the recent change in the treatment landscape of advanced non-small cell lung cancer (NSCLC) and what we can expect in the future. There have been great advances in the treatment of advanced NSCLC, however an increase in the number of treatment options brings rise to new challenges and questions that need to be dealt with. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates